|
|
Other links at Articles > Dermatology |
| 2. |
Effect of Imiquimod on Nodular Basal Cell Carcinoma Modest
|
|
|
Imiquimod applied three times a week for 8 or 12 weeks shows some activity against nodular basal cell carcinoma, results of a study published in the October issue of the Journal of the American Academy of Dermatology indicate. Reuters Health Information
|
| 4. |
Sorafenib Plus Dacarbazine Shows Promise in Advanced Melanoma
|
|
|
In a phase II study of chemotherapy-naive patients with stage III (unresectable) or stage IV melanoma, the addition of the Raf kinase inhibitor sorafenib to dacarbazine yielded an "encouraging" improvement in progression-free survival, the primary endpoint, and was well tolerated, researchers report. Reuters Health Information
|
|
|
